Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists

被引:8
|
作者
Khedagi, Apurva [1 ]
Hoke, Cara [2 ]
Kelsey, Michelle [2 ]
Coviello, Andrea [3 ]
Jones, W. Schuyler [2 ]
Jackson II, Larry R. [2 ]
Patel, Manesh R. [2 ]
McGarrah, Rob W. [2 ]
Pagidipati, Neha J. [2 ]
Shah, Nishant P. [2 ,4 ]
机构
[1] Duke Univ, Sch Med, Dept Med, Durham, NC USA
[2] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA
[3] Duke Univ, Sch Med, Div Endocrinol Metab & Nutr, Durham, NC USA
[4] 2301 Erwin Rd, Durham, NC 27705 USA
来源
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2023年 / 13卷
关键词
Disparities; Prevention; Health equity; SGLT2i; GLP1-RA; CORONARY-HEART-DISEASE; SOCIOECONOMIC-STATUS; CARDIOVASCULAR OUTCOMES; GENDER-DIFFERENCES; HEALTH; DISPARITIES; PREVENTION; RISK; EXENATIDE; FAILURE;
D O I
10.1016/j.ajpc.2023.100477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Among the most prominent disparities within cardiovascular disease prevention are with the use and distribution of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. Several landmark trials have demonstrated the efficacy of these novel agents, not only in cardiovascular disease prevention among those with diabetes, but also in heart failure and chronic kidney disease. However, the use of these agents remains limited by disparities in certain racial/ethnic, sex, and socioeconomic groups. This review works to highlight and understand these differences on the use and prescribing patterns of pivotal agents in cardiovascular disease prevention, SGLT-2 inhibitors and GLP-1 agonists. Our aim is to enrich understanding and to inspire efforts to end disparities in cardiovascular morbidity and mortality due to race, sex and income inequality.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] GLP-1 receptor agonists in comparison with SGLT-2 inhibitors
    Pavlicek, Vojtech
    DIABETOLOGE, 2020, 16 (05): : 530 - 531
  • [2] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
  • [3] Mortality Differences SGLT-2, DPP-4 Inhibitors and GLP-1 Receptor Agonists
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (03): : 173 - 173
  • [4] Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
    Bailey, Clifford J.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (02): : 97 - 99
  • [5] Impact of GLP-1 receptor agonists versus SGLT-2 inhibitors on diabetic retinopathy
    Joo, Julia
    Sharma, Neha
    Daugirdas, Sarunas
    Wu, Anna K.
    Russell, Matthew W.
    Skugor, Mario
    Singh, Rishi
    Rachitskaya, Aleksandra V.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [6] Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists
    Chen, Jia-Jin
    Lee, Tao-Han
    Yang, Huang-Yu
    KIDNEY INTERNATIONAL, 2024, 105 (03) : 442 - 444
  • [7] Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Prattichizzo, Francesco
    Candia, Paola de
    Ceriello, Antonio
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 120
  • [8] Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
    Dadwani, Rahul S.
    Wan, Wen
    Skandari, M. Reza
    Huang, Elbert S.
    MDM POLICY & PRACTICE, 2023, 8 (02)
  • [9] SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation
    Arnold, Michael J.
    Buelt, Andrew
    AMERICAN FAMILY PHYSICIAN, 2022, 105 (06) : 675 - 677
  • [10] GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease
    Sun, Ryan
    Srivastava, Anand
    Derebail, Vimal K.
    Han, Jin
    Molokie, Robert E.
    Gordeuk, Victor
    Saraf, Santosh L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1610 - 1612